Affiliation:
1. Departments of Internal Medicine “A” Assaf Harofeh Medical Center, Zerifin, with Sackler Faculty of Medicine, Tel Aviv University
2. Nephrology, Assaf Harofeh Medical Center, Zerifin, with Sackler Faculty of Medicine, Tel Aviv University
3. Kimron Veterinary Institute, Beit Dagan, Israel
Abstract
ObjectiveThe objective of this study was to assess the pharmacokinetics of intraperitoneal (IP) administration of the antibiotic combination piperacillin/tazobactam (PIP/TAZ) to patients on chronic ambulatory peritoneal dialysis (CAPD) with and without pseudomonas peritonitis.DesignOpen-labeled study.SettingThe study was carried out in the CAPD unit of Assaf Harofeh Medical Center, Zerifin, Israel.Patients and MethodsSix patients participated in the study, 4 had pseudomonas peritonitis, all were given an IP loading dose of 4 g/0.5 g PIP/TAZ. Twenty-four hours after the initial dose, a maintenance dose of 0.5 g/0.0625 g PIP/TAZ was administered with each dialysate exchange for a period of 1 week. The patients without peritonitis received only the loading dose. High performance liquid chromatography was used to determine the concentrations of PIP/TAZ in plasma obtained at 0, 30, 60, 90, 120, 360, 480, 600, 720, and 1440 minutes after administration. Samples of the dialysate fluid for determination of PIP/TAZ concentration were collected at 6, 10, 14, 24, and 72, 120, and 168 hours.ResultsAfter the loading dose, the highest plasma PIP concentration (Cmax) was 51.6 ± 21.25 μg/mL and appeared at 1.5 ± 0.45 hours (tmax). During the maintenance period plasma PIP concentration was 5.2 ± 4.75 μg/mL. Tazobactam was detected in the plasma of 1 patient only. The concentration of TAZ in the dialysate fluid during the maintenance period was 2.3 ± 0.5 μg/mL.ConclusionsPiperacillin administered IP at 4 g reached plasma concentrations comparable to intravenous administration and considered therapeutic (above the MIC90for Pseudomonas aeruginosa) in CAPD patients with or without peritonitis. The maintenance dose, however, should be augmented. Tazobactam could not be detected in the plasma of most patients and the therapeutic implications of IP administration of TAZ cannot be directly correlated to intravenous administration.
Subject
Nephrology,General Medicine
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Pharmacokinetics of intravenous piperacillin/tazobactam among patients with peritoneal dialysis-associated peritonitis;Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis;2024-04-26
2. Pharmacokinetic and Pharmacodynamic Basis of Optimal Antimicrobial Therapy;Principles and Practice of Pediatric Infectious Diseases;2023
3. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment;Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis;2022-03
4. Anti-Infective Agents;Demystifying Drug Dosing in Renal Dysfunction;2019-05-31
5. Pharmacokinetic-Pharmacodynamic Basis of Optimal Antibiotic Therapy;Principles and Practice of Pediatric Infectious Diseases;2018